US EditionTrump to Announce ‘TrumpRx’ Drug-Buying Website and Deal With Pfizer to Lower Drug Prices: Report
- President Donald Trump will announce an agreement with Pfizer to voluntarily lower drug prices, as confirmed by a White House official.
- Pfizer will launch a direct-to-consumer website called TrumpRx for purchasing medication, according to senior administration officials.
- Trump signed an executive order in May directing federal officials to link drug prices in the U.S. to those in other wealthy countries, indicating his administration's ongoing efforts to reduce costs.
- A Pfizer spokesperson confirmed that the agreement with the Trump administration has been reached to lower medication prices in the U.S., reflecting the administration's focus on drug affordability.
250 Articles
250 Articles
In May, US President Trump declared war on high drug prices in the US by executive order. Now, Pfizer is the first manufacturer to comply with Trump's demands and announce it will lower prices. Other pharmaceutical companies are expected to follow suit.
Iowa Pharmacy Association's pros & cons of Trump-Pfizer deal
DES MOINES, Iowa -- In May President Trump called on drug makers to lower their prices, and on Tuesday the first large pharmaceutical company gave in. Pfizer and the Trump administration struck a deal to lower some costs of drugs to Medicaid patients. The agreement will result in a website called “TrumpRX”. As part of the deal, Pfizer will sell some of its primary care medicines on this new direct-to-consumer website. They say discounts will av…
Stock Market Today: Pfizer Rallies on Trump Drug Pricing Deal and U.S. Investment Pledge @themotleyfool #stocks $PFE $^GSPC $JNJ $^IXIC $LLY
Pfizer Inc (NYSE: PFE) closed at $25.48, rising 6.83%. Volume soared to over 153 million shares, nearly 3.5 times its three-month average of 43.3 million. Indexes advanced modestly, led by healthcare and industrial strength. The S&P 500 (SNPINDEX: ^GSPC) gained 0.41% to 6,688.46, and the Nasdaq Composite (NASDAQINDEX: ^IXIC) ticked up 0.30% to 22,660.01, as health and industrial sectors led gains. Among large pharma peers, Johnson & Johnson (NYS…
Coverage Details
Bias Distribution
- 57% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
